Work Here?
Overview
Caribou Biosciences develops allogeneic CAR-T cell therapies using a CRISPR-based chRDNA platform (Cas9 and Cas12a) to create precise genome edits. Its lead approach centers on off-the-shelf, armored CAR-T cells designed to persist longer and resist exhaustion, including PD-1 knockout, enabling rapid access for patients. The company advances wholly-owned programs and collaborates with pharma partners, such as AbbVie, to push its therapies through clinical development. Its goal is to bring regulated, off-the-shelf CAR-T therapies to patients with hematologic cancers and autoimmune diseases and to reach commercialization, supported by funding through at least 2027.
About Caribou Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Berkeley, California
Founded
2011
Simplify's Take
What believers are saying
- CB-011's 92% overall response rate supports expansion in relapsed or refractory multiple myeloma.
- FDA alignment on ANTLER-3 gives vispa-cel a clear phase 3 path in LBCL.
- Caribou's January 2025 CFO and CMO appointments strengthen late-stage execution and financing.
What critics are saying
- CB-010 remains the only near-term value driver; one weak readout can crush the stock.
- Allogeneic CAR-T faces rejection, persistence, and manufacturing consistency problems Caribou still has not solved.
- CB-012 targets AML, where durable allogeneic cell-therapy success remains unproven and partnering value stays weak.
What makes Caribou Biosciences unique
- Caribou's chRDNA platform enables precise Cas9 and Cas12a edits for allogeneic CAR-T.
- CB-010 pairs TRAC knockout, CD19 insertion, and PD-1 deletion in one product.
- CB-011 uses B2M-HLA-E immune cloaking to blunt T-cell and NK-cell rejection.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$618.6M
Above
Industry Average
Funded Over
8 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Tuition Reimbursement
Generous paid vacation time
Comprehensive compensation package
ESPP
Stock Price
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↓ -4%2 year growth
↑ 8%Caribou Biosciences announced the appointment of Sri Ryali as Chief Financial Officer, effective January 2, 2025.
Mr. O'Byrne joins Vir from Caribou Biosciences, Inc., where he served as CFO, leading the finance, investor relations, corporate communications, IT, procurement, and operations functions as the company advanced its pipeline of clinical-stage cell therapies in oncology and autoimmune disease.
Caribou Biosciences (CRBU) has appointed Dr. Tina Albertson as its new Chief Medical Officer.
Caribou Biosciences is cutting its CAR-NK research and laying off 21 employees, or 12% of its staff, the company announced Tuesday.
Caribou Biosciences announces appointment of Terri Laufer, MD, to its scientific advisory board.
Caribou Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Caribou Biosciences
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Berkeley, California
Founded
2011
Caribou Biosciences is Hiring for 2 Jobs on Simplify!
Find jobs on Simplify and start your career today